Hydrogen Research Study
← Back to Research Library
Human clinical evidenceHuman Clinical StudyOther or not reported

Abstract 397: Hydrogen Inhalation in Combination With Hypothermic Temperature Control Improves Survival After Out-of-Hospital Cardiac Arrest

Koji Minami, Tomoyoshi Tamura, Hiromichi Narumiya, Masaru Suzuki · Circulation · 2023

Research-use notice

Independent study record

Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.

H2HUBB Research Library branded molecular hydrogen research image
Primary topic Cardiovascular Health
Evidence type Human clinical evidence
Publication type Human Clinical Study
Hydrogen method Other or not reported

H2HUBB TAKEAWAY

These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.

What the Findings Mean

H₂ in combination with hypothermic TTM improved 90-day survival after OHCA but not under normothermic TTM.

What the Researchers Studied

The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.

What Effects Did Molecular Hydrogen Have?

Reported treatment duration: 18 hours. H₂ in combination with hypothermic TTM improved 90-day survival after OHCA but not under normothermic TTM.

Why These Findings Matter

These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.

How Strong Is This Evidence?

This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.

Technical Study Details

H2HUBB classifies this publication as human clinical study with human clinical evidence. The study used a randomized human clinical trial. The reported treatment duration was 18 hours.

Limitations and Safety

No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.

Original Study and H2HUBB Research Context

H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.